首页 | 本学科首页   官方微博 | 高级检索  
检索        

林蛙油治疗绝经后骨质疏松症的临床研究
引用本文:王丹辉,贲越,韩梅.林蛙油治疗绝经后骨质疏松症的临床研究[J].中医正骨,2014(1):27-30,37.
作者姓名:王丹辉  贲越  韩梅
作者单位:[1]吉林省中医药科学院,吉林长春130021 [2]吉林省长春市中医院,吉林长春130021 [3]广东省广州市红十字会医院,广东广州510000
基金项目:吉林省中医药管理局资助项目(2012-115),长春市科技计划科技项目(2012114)
摘    要:目的:观察林蛙油治疗绝经后骨质疏松症的临床疗效,并探讨其作用机制.方法:将60例绝经后骨质疏松症患者随机分为治疗组和对照组,每组30例,治疗组采用口服林蛙油治疗,对照组采用口服仙灵骨葆胶囊治疗.治疗6个月后,观察2组患者治疗前后临床症状体征评分改变及骨密度、骨代谢指标变化情况.结果:①症状体征评分.治疗前2组患者症状体征评分比较,差异无统计学意义(t=1.781,P=0.113);治疗6个月后,2组患者症状体征评分均较治疗前降低(17.67 ±3.67)分,(6.44±2.46)分,t=13.808,P=0.000;(20.22 ±2.17)分,(11.89±1.90)分,t=15.811,P=0.007],治疗组降低更明显(11.23±2.44)分,(8.33±1.58)分,t=2.760,P=0.025].②骨密度.治疗前和治疗6个月后,2组患者骨密度比较,组间差异均无统计学意义(t =0.824,P=0.425;t=0.767,P=0.457);治疗6个月后,2组患者骨密度与治疗前比较,差异均无统计学意义(-2.37±0.84)g· cm-2,(-2.65±0.91)g·cm-2,t=0.811,P=0.432;(-2.19±0.83)g·cm-2,(-2.41±0.56)g· cm-2,t =0.727,P=0.479].③骨代谢指标.治疗前2组患者骨碱性磷酸酶、雌二醇、白细胞介素-6、骨钙素血清含量比较,组间差异均无统计学意义(t=1.622,P=0.127;t=1.114,P=0.284;t=1.554,P=0.143;t=1.185,P=0.160).治疗6个月后,2组患者血清骨碱性磷酸酶含量(17.13±2.13)单位·L-1,(7.80±1.82)单位·L-1,t=12.594,P=0.000;(16.40±1.80)单位·L-1,(10.73±2.12)单位·L-1,=8.324,P=0.000]、血清白细胞介素-6含量(125.20±13.86) μg·L-1,(88.13±10.20) μg·L-1,t=5.795,P=0.000;(131.93±11.07)μg· L-1,(107.40±7.74) μg·L-1,t=9.648,P=0.000]、血清骨钙素含量(6.19±0.96) ng·L-1,(3.54±1.12)ng·L-1,t=6.504,P=0.000;(5.80 ±0.56)ng·L-1,(5.15±0.51)ng·L-1,t=6.733,P=0.000]均较治疗前降低,治疗组降低更明显(9.33±2.87)单位·L-1,(5.67 ±2.64)单位·L-1,t=7.416,P=0.000; (37.17±19.08) μg·L-1,(24.53 ±9.85)μg·L-1,t=2.253,P=0.041;(2.65±1.53)ng·L-1,(0.64 ±0.37)ng·L-1,t =4.820,P=0.000];2组患者血清雌二醇含量均较治疗前升高(21.73±5.55) pg·mL-1,(43.40±5.65) pg·mL-1,t=8.208,P=0.000;(24.27±7.72)pg·mL-1,(34.13±5.75)pg· mL-1,t=5.006,P=0.000],治疗组升高更明显(21.67±10.22)pg· mL-1,(9.87±7.63)pg·mL-1,=4.209,P=0.001].结论:林蛙油在短期内未能提高绝经后骨质疏松症患者的骨密度,但可以明显提高其血清雌二醇水平,降低其血清骨碱性磷酸酶、白细胞介素-6和骨钙素水平,这可能是林蛙油可以明显改善PMOP患者的临床症状与体征的作用机制之一.

关 键 词:骨质疏松  绝经后  林蛙  仙灵骨葆胶囊  治疗  临床研究性  骨密度  碱性磷酸酶  骨钙素  雌二醇  白细胞介素6

Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis
Wang Danhui,Ben Yue,Han Mei.Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014(1):27-30,37.
Authors:Wang Danhui  Ben Yue  Han Mei
Institution:. * Jilin Academy of Traditional Chinese Medical Sciences, Changchun 130021, Jilin, China
Abstract:Objective:To observe the clinical effects of Rana temporaria oil on postmenopausal osteoporosis(PMOP) and to explore its mechanisms of action. Methods:Sixty patients with PMOP were randomly divided into treatment group and control group,30 cases in each group. The patients in treatment group were treated with Rana temporaria oil, while the others in control group were treated with XIANLING GUBAO capsules. The changes in clinical symptoms and signs scores, bone density and bone metabolism index were observed and compared between the 2 groups before and after 6-month treatment. Results:There were no statistical difference in the symptoms and signs scores be- tween the 2 groups before the treatment (t = 1.781, P = 0.113 ). while the symptoms and signs scores decreased in both of the 2 groups after 6 - month treatment( 17.67 ~-3.67 vs 6.44 ~- 2.46 points,t = 13. 808 ,P = 0. 000;20.22 ~- 2.17 vs 11.89 4-/- 1.90 points,t = 15.811,P = 0. 007), and the scores decreased more significantly in the treatment group (11.23 ~-2.44 vs 8.33 ~- 1.58 points, t =2. 760 ,P = 0. 025 ). There were no statistical difference in bone density between the 2 groups before the treatment and after 6 - month treat- ment(t = 0. 824 ,P = 0. 425;t = 0. 767 ,P = 0. 457 ). There were no statistical difference in bone density between pre - and post-treatment ( -2.37 4,/-0.84 vs -2.65 +/-0.91 g/cm(2) ,t =0. 8ll ,P =0. 432; -2.19 +/-0.83 vs -2.41 +/-0.56 g/cm(2) ,t =0. 727 ,P = 0. 479 ). There were no statistical difference between the 2 groups in the serum concentrations of bone alkaline phosphatase, estradiol, inter- leukin-6 and osteocalcin before the treatment(t = 1. 622,P =0. 127;t = 1. l14,P =0. 284;t = l. 554,P =0. 143;t = 1. 185,P =0. 160). The serum concentrations of bone alkaline phosphatase( 17.13 +/-2.13 vs 7.80 +/-1.82 units/L, t = 12. 594 ,P--0. 000;16.40 +/-1.80 vs 10.73 +/- 2.12 units/L, t = 8. 324, P = 0. 000), interleukin-6 ( 125.20 4/- 13.86 vs 88.13 4/- 10.20 ~g/L, t = 5. 795, P = 0. 000 ; 131.93 4/- 11.07 vs 107.40 4/- 7.74 Ixg/L, t = 9. 648, P = 0. 000 ) and osteocalcin ( 6.19 4/- 0.96 vs 3.54 +/- 1.12 ng/L, t = 6. 504, P = 0. 000 ;5.80 +/- 0.56 vs 5.15 +/- 0.51 ng/L,t = 6. 733, P = 0. 000) decreased in both of the 2 groups after 6-month treatment, and more significant decrease were found in the treatment group(9.33 +/-2.87 vs 5.67 +/-2.64 units/L, t = 7. 416, P = 0. 000 ; 37.17 +/- 19.08 vs 24.53 4-/- 9.85 Ixg/L, t = 2. 253, P = 0. 041 ;2.65 +/- 1.53 vs 0.64 +/- 0.37 ng/L, t = 4. 820, P = 0. 000) ; The serum concen- trations of estradiol increased in both of the 2 groups after 6-month treatment (21.73 +/- 5.55 vs 43.40 +/- 5.65 pg/mL, t = 8. 208, P = 0. 000;24.27 +/-7.72 vs 34.13 +/-5.75 pg/mL,t =5. 006,P =0. 000) ,and more significant increase were found in the treatment group (21.67 +/- 10.22 vs 9.87 ~-7.63 pg/mL,t = 4. 209,P = 0. 001 ). Conclusion: Although the Rana temporaria oil can not improve bone mineral density in patients with postmenopausal osteoporosis in short period,it can increase the serum estradiol level significantly and de- crease the serum concentrations of bone specific alkaline phosphatase, interleukin-6 and osteocalcin,which may be one of the mechanisms of action for Rana temporaria oil to obviously improve clinical symptoms and signs of PMOP patients.
Keywords:Osteoporosis  postmenopausal  Rana temporaria  XIANLING GUBAO capsule  Therapies  investigational  Bone Density  Alka- line phosphatase  Osteocalcin  Estradiol  Interleukin-6
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号